The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
OBJECTIVE
To determine the relationship between apolipoprotein E (APOE) polymorphisms to the time to appearance of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.


METHODS
The APOE genotype of 155 consecutive patients treated with levodopa was determined and its effect on the time of onset of LID was examined using Cox regression model, controlling for gender, age of disease onset, time to initiation of levodopa treatment and history of smoking.


RESULTS
Two patients were homozygous for the APOE ε2 allele, 7 had ε2/ε3, 1 had ε2/ε4, 130 had ε3/ε3, 12 had ε3/ε4 and 3 had ε4/ε4; LID appeared in 57.4% of the patients, appearing 4.1 ± 3.5 years after the initiation of levodopa treatment. The survival curve for LID was not affected by the APOE genotype (P = 0.34).


CONCLUSIONS
APOE polymorphisms were found not to be associated with either the occurrence or the time to development of LID.
Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Tel-Aviv, Israel.
I
I
Molchadski
A D
AD
Korczyn
O S
OS
Cohen
A
A
Katzav
Z
Z
Nitzan
J
J
Chapman
S
S
Hassin-Baer
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001057:Apolipoproteins E / Q000235:genetics*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000235:genetics* / Q000401:mortality; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D012189:Retrospective Studies
D000978:Antiparkinson Agents; D001057:Apolipoproteins E; D007980:Levodopa